Comparison
Magnesium L-Threonate vs Vinpocetine
Magnesium L-Threonate
MIT-developed magnesium that crosses the blood-brain barrier. Shown to enhance synaptic density and reduce 'brain age'.
Vinpocetine
Semi-synthetic derivative of vincamine from periwinkle. Increases cerebral blood flow.
| Field | Magnesium L-Threonate | Vinpocetine |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–2000mg | 5–30mg |
| Half-life | 6h | 2h |
| Onset | — | — |
| Evidence | EVIDENCEB | EVIDENCEB |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USBanned |
| PubMed refs | 90 | 600 |
The comparison in plain English
Auto-generated from dataMagnesium L-Threonate and Vinpocetine are both in the neuroprotective category respectively. Magnesium L-Threonate MIT-developed magnesium that crosses the blood-brain barrier. Vinpocetine Semi-synthetic derivative of vincamine from periwinkle.
Bottom line
Magnesium L-Threonate (evidence B, safety 5/5) matches the evidence base of Vinpocetine (evidence B, safety 4/5). Magnesium L-Threonate has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Magnesium L-Threonate if
Magnesium L-Threonate is the better fit when your goal aligns with its mechanism (L-threonate is a sugar-acid carrier that uniquely enables magnesium to cross the blood-brain barrier in meaningful quantities — most oral magnesium forms (oxide, citrate, glycinate) raise serum magnesium but not central magnesium) and the dose range (1000–2000mg) suits your protocol. Half-life is 6h.
Choose Vinpocetine if
Vinpocetine is the better fit when your goal aligns with its mechanism (Inhibits phosphodiesterase 1 (PDE1), increasing intracellular cGMP and producing vasodilation specifically in cerebral arterioles) and the dose range (5–30mg) suits your protocol. Half-life is 2h.